StockNews.com Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Buy

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.

Other equities analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. Royal Bank of Canada restated an “outperform” rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Chardan Capital lowered their price objective on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Finally, Wells Fargo & Company cut their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $215.88.

Alnylam Pharmaceuticals Trading Down 2.3 %

NASDAQ:ALNY opened at $143.95 on Monday. The business’s 50-day moving average is $150.22 and its 200 day moving average is $165.63. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $218.88. The company has a market capitalization of $18.13 billion, a P/E ratio of -41.39 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. During the same period last year, the company earned ($1.68) earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis. On average, research analysts forecast that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALNY. Harbor Capital Advisors Inc. grew its stake in Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,887 shares of the biopharmaceutical company’s stock worth $511,000 after acquiring an additional 163 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in Alnylam Pharmaceuticals by 9.1% in the third quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 363 shares in the last quarter. Xponance Inc. increased its holdings in Alnylam Pharmaceuticals by 0.7% during the 3rd quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock worth $2,654,000 after purchasing an additional 109 shares during the period. Raymond James & Associates raised its position in Alnylam Pharmaceuticals by 5.1% during the 3rd quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company’s stock valued at $2,198,000 after purchasing an additional 598 shares in the last quarter. Finally, Forsta AP Fonden lifted its holdings in shares of Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Forsta AP Fonden now owns 25,400 shares of the biopharmaceutical company’s stock worth $4,498,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.